Eylea® (aflibercept) injection sbla for every 16-week dosing regimen in patients with diabetic retinopathy accepted for fda review

If approved, extended regimen would provide a longer treatment interval and additional dosing flexibility, alongside approved every 4- and 8-week dosing regimens tarrytown, n.y. , june 29, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced the u.s. food and drug administration (fda) has accepted for review the eylea® (aflibercept) injection supplemental biologics license application (sbla) for an every 16-week 2 mg dosing regimen (after initial monthly doses) in patients with diabetic retinopathy (dr).
REGN Ratings Summary
REGN Quant Ranking